A B S T R A C T The ability of highly purified human leukocytic pyrogen (LP) to induce neutrophil lysosomal protein release is described. Human peripheral blood neutrophils isolated by Ficoll-Hypaquie and dextran sedimentation were exposed to purified human LP. The specific granule-associated proteins, lysozyme and lactoferrin were selectively released, whereas primary granule (,8-glucuronidase) and cytoplasmic (lactic dehydrogenase) enzyme markers were not. Optimum release was obsprved after 45 min in the presence of Ca++ and Mg++. Cytochalasin B (5 ,ug/ml) had no effect on LP-induced lysosomal enzyme release. Since the pyrogenicity of LP is dependent on prostaglandin synthesis, the effect of two potent inhibitors of prostaglandin synthesis on lysozyme release was studied. Both indomethacin and naproxen failed to inhibit specific granule protein release. These observations suggest that the concommitance of fever, elevated serum or urine lysozyme and hypoferremia may, in part, be explained by the interaction of LP and peripheral blood neutrophils.
INTRODUCTION
Fever, whether present in inflammatory or infectious diseases, is mediated by a small, molecular weight (15, 000 daltons) protein called leukocytic pyrogen (LP)l (1) . In addition to its ability to elevate temperature, LP has been shown to acutely reduce serum iron, and this hypoferremia is dependent on the presence of neutrophils because it does not occur in neutropenic animals (2) . Lactoferrin, an iron-binding protein found in neutrophil-specific granules is thought to be the necessary granulocyte factor responsible for hypoferremia (3) . Another specific granule constituent, lysozyme, is Received for publication 14 September 1977 and in revised form 16 December 1977. ' Abbreviations used in this paper: HBSS, Hanks' balanced salt solution; LP, leukocyte pyrogen; RPD, rabbit pyrogenic dose.
markedly reduced in neutroph-ils obtained from patients with acute febrile infections (4) . In addition, the constellation of fever, reduced serum iron, hypoferremic anemia, and elevated serumil or urinie lysozyme has beeni demonstrated in several inflammatory diseases (5) (6) (7) . These observations suggested to us that LP, in addition to mediatinig fever, might directly interact with the neutrophil and result in release of' neutrophil granule constituents.
In this report, wve demiionistrate that smiiall amounts (:10 nM) of highly purified human LP caause selective release of specific grantule contents from neutrophils. Degranulation takes place in the absence of phagocytosis, adherence to suirf;aces, or cytochalasin B. This is the first report of a physiologic substance whielh releases lysosomal contents withouit other cellular maniipuilation and these observations mlay, in part, provi(le the basis for hypoferremia and elevated seruim or uirine lysozyme in several febrile inflammatory dliseases.
METHODS

Preparation of neutrophils. Heparinized venous blood
was collected from healthy adult volunteers and centrifuged on Ficoll-Hypa(Ique gradients followed by dextran sedimentation (8) . Erythrocytes were lysed with hypotonic saline and the resulting leukocyte suspension *was washed twice in Hanks' balanced salt solutioni (HBSS, National Instituites of Health media unit) containing 1.0 mM CaCI2 and 0.5 mM MgCl2. Leukocytes obtainie(d in this manniier conitaine(d 96-98% neutrophils.
Preparation of human LP. Human LP was preparecl from monontuclear cells as described previouisly (9) . Crtude stupernates containing LP were concentrated in auitoclaved dialysis ttubing in front of a high-speed fan. Volumes were reducted 1/20 and dialyzed against phosphate-buffere(d saline with 0.02% sodium azide. Concenitrated LP was l)laced over anl immunoadsorbant column conitaining rabbit anti-humlan LP antibody attached to CNBr-activated Sepharose. LP was eluted from this material in citric acid buffer, pH 3.2 (10), neutralized with 0.1 M NaOH, anid stored in 0.02% Na azide. LP eluted from the anti-LP immuntioadsorbanit was concentrated and chromatographed over Sephadex G-50 (fine) (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) (165 x 5.6 cm) at 4°C in phosphate-buffered saline with 0.02% Na azide. The 15,000 mol wt LP peak was isolated, dialyzed against H2O, and lyophilized. This material gave a single staining band on 7.5% polyacrylamide gels in 0.1% sodium dodecyl sulfate.
As described, further purification of human LP was carried out using 1251-labeled LP (11, 12) . A small (Itiantity of this homogeneous radiolabeled LP ( Fig. 1 ) (_ 1,000 epm) was added to unlabeled LP isolated from Sephadex G-50. This material was chromatographed over G-15 followed by DEAE ion-exchange and, in each case, the radioactivity peak was used to indicate purified unlabeled LP. Since biologic activity of LP decreased significantly during the ion-exchange step, 0.1% albumin was added to each collection tube to prevent nonspecific adsorbtion. Recovery of biologic activity was between 1 and 2% of the starting concentrated crude LP.
Rabbit pyrogen assay. Details concerning housing, training, and temperature recordings have been reported elsewhere (13) . To determine the number of' pyrogenic doses in preparations of human LP, a two-point dose-responise was employed using six rabbits as described elsewhere (10, 13) . For the present study, peak fever occurring in rabbits between 0.6 and 1.0°C was considered a rabbit pyrogenic dose (RPD) and in a previouis report has been estimated to contain 50 ng or less of the purified LP protein (12) . Based on the 15,000-dalton mol wt of' human LP, 1 RPD/ml is s30 nM.
Incubation conditions. Neutrophils were adjusted to 1.0 x 107 or 5 x 107 cells/ml in HBSS. For some experiments, the concentrations of CaCl2 and MgCl2 were varied to examine the divalent cation effect on lysosomal protein release. Neutrophil suspensions were then incubate'd for 45 min at 37°C in a shaking water bath in media alone or in the presence ofLP. LP was dialyzed against HBSS or H2O to remove sodium azide. For inhibitor or enhancement experiments, cells were preincubated with the pharmacologic agent or media alone followed by the usual 45-min incubation period. After incubation, cells were centrifuged at 400 g for 10 min at 4°C and the supernates were collected.
Enzyme (17) .
For these studies, neutrophils were suspended in HBSS at 5 x 107 cells/ml and incubated with LP (10 RPD/ml) as previously described. After incubation, supernates and freezethawed cell lysates were extracted in 1 M NaCl at 4°C overnight (18) . The specimens were then centrifuged for 30 min at 20,000 g 4°C to remove insoluble material. Radial immunodiffusion plates were prepared using commercially obtained rabbit antisera to human lactof'errin (Behring Diagnostics, Somerville, N. J. 
RESULTS
Enzyme release. Semipurified preparations of human LP which had been eluted from anti-LP immunoadsorbants followed by gel filtration on Sephadex G-50 contained no detectable lysozyme, f3-glucuronidase, lactic dehydrogenase, or lactoferrin. Over a wide concentration range, LP caused selective extracellular release of lysozyme with little or no release of,8-glucuronidase (Fig. 2) . Furthermore, there was consistently <4% of total lactic dehydrogenase activity in the incubation media, indicating that lysozyme release was not a result of cell death. Significant release of lysozyme was observed at LP concentrations of 1 RPD/ml. Maximal enzyme release occurred by 20 RPD/ml and higher LP concentrations did not result in additional lysozyme release. By light microscopy, neutrophils exposed to 10 RPD/ml, which had released _ 20% of total lysozyme, did not appear vacuolated and there was no gross change in cytoplasmic granularity. Heating these preparations of LP at 80°C for 15 min or precipitation in the presence of NaCl during lyophilization, procedures which destroy the pyrogenicity ofhuman LP, destroyed its ability to release lvsozyme. Fuirthermiiore, large pvrogenic doses of endotoxin (300 gg/ml) (E.scherichia coli endotoxin, Difco Laboratories, Detroit, Mich.) ha(l I10 effect on lysosomal release utider these conditions. Therefore, the ability of these semiptirified preparations of human LP to release lvsozvmI1re wvas not dute to contamination hv endotoxin. In addition, preparations of LP were negative in the Lirnulwis amehocvte lvsate test (20) .
To ascertain that the LP molecule was responisible for releasing lysozyme in the above experimiients, fuirther purification methods were employed. 500 RPD were purified using immuinoadsorbance, gel filtration over G-50, G-15, and DEAE ion-exchange as (lescribedl in Methods. Humilan serulm alblumini (0.1'7%) was acddedl to the collection tules f'rom01 the final ion-exchange column to protect the molecule againist nonispecific losses. Despite stuch measures, only five RPI) of purified LP were recovered. \Vhen this preparationi was divided into two samples and incuhated with neuitrophils, the quantity of lysosyme releatse was 16.54()0.2%c which is comparable to the amiiotunit of lysozyvmle released Iv 2.5 RPD/ml (Fig. 2) sponse was observed. Nevertheless, enzyme release wvith either divalent cation alone was not simply additive and the two cations together act synergistically (four sample paired t test P < 0.05). 8-Glucuronidase release remained <8% in all these experiments (data not shown). Failure to effect LP-induced enzyme release by indomethacitn, naproxent, or cytochalasitn B. LP is thought to produce fever by inducing local prostaglandin synthesis in the hypothalmus (23) . WAe therefore investigated the effect of two potent prostaglandin inhibitors on enzyme release induced by LP. Neutrophils were preincubated for 15 min with various concentrations of indomethacin (1-100 ,uM) or naproxen at 100 juM.
After preincubation, LP was added at 5 or 20 RPD/ml and the incubation continued for an additional 45 min. As shown in Fig. 4 , there was no significant effect on enzyme release by either agent. Even on the steep portion of the dose-response curve (5 RPD/ml) no inhibitorv effect could be demonstrated. To insure that these agents inhibited prostaglandin synthesis, netutrophils (1 x 107/ml in HBSS) were preincubated with indomethacin (1 or 100 ,uM) or buffer at 37°C for 15 min. Arachadonic acid (10 ,ug/ml, Sigma Chemical Co.) was then added and the incubation continued for 15 (24) . To determiinie if cytochalasin B caused a similar enhancement of enzyme release when LP was the stimulus, neutrophils vere preincubated vith cytochalasin B (5 ,g/ml) for 10 min. After preincubation LP (5 RPD/ml) was added and the incubation continued for 45 mill In three separate experiments, cells in buffer or cytochalasini B without LP released 8.2 ±1.4 and 7.3±0.6% total lysozymlle, respectively (P > 0.05). Similarly, in the presenice of' LP there was no enihancement of lysozyme release witlh cytochalasin B (20.1±1.2% for LP in buffer vs. 21 .2±+1.4% for LP after cytochalasin B, P > 0.05). ,-Gllucuronidase release was also unlaffected I)v cytochalasinl B (not showni).
DISCUSSION
The results of this study demonstrate that a biologically produced human protein, LP, is capable of induciing lysosomal protein release in the absence of phagocytosis, adherence, or cytochalasin B treatment. Other nanaturally occurring serum substances which induce degranulation, such as chemotactic f;ators, all re(quire perturbation of' the neutrophil membrane with cytochalasin B or adherence to a filter to result in secretion (25, 26) . Thus, LP represents a naturally occurring small molecular weight protein which can initiate release of specific granule contenits fromii cells in suspension without other perturbation of the cell membrane.
The selectivity for the release of' specific granule contents is in keeping with several previous observations that these proteins are more accessible for extracellular release. Studies by Wright and Malawista (27) have shown that under coniditions of phagocytosis, lysozyme release was easily demonstrated, whereas certain acid hydrolases associated with peroxidase-positive granules were only minimally released. Lefell and Spitznagel (28) have made similar observations when the degranulating stimulus was immune complex. More recently, selective mobilization of' specific granule associated enzymes has been shown with the pharmacologic agents coneanavalin A, phorbol myristate acetate, and ionophore A23187 (29) (30) (31) (32) 22) . In this regard, it is of particular interest that LP follows a similar pattern of selective release of specific granule contents including a re(quirement for calcium and magnesium for optimal release. The extracellular release of lysozyme and lactoferrin in the absence of'/3-glucuronidase provides strong evidence that the enzyme-mobilizing effect of' LP is primarily on specific granules (33) . Furthermore, assaying for 8-glucuronidase during our kinetic studies failed to show significant release of' this einzyme even at early time points (not shown). Because recovery of LP from the purification procedure is low (1%), it was not possible to assess the effect of higher concentrations on enzyme release. As is the case with ionophore A23187, it is possible that the selectivity for release of' specific granule contents might be abolished at greater LP concentrations (32) . The lack of an inhibitory effect of' indomethacin and naproxen suggests that the LP-induced release is independent of de novlo prostaglandini synithesis.
Our in vitro observationi that LP is a sufficient stimulus to induce neutrophil specific granule protein release when neuitrophils are in suspension may have direct cliniical relevance. Acute hypoferremia has been slhown to oceur in both man and animals after the injection of bacterial endotoxin and to accompany a variety of inflammatory diseases (34, 35, 6) . Even apyrogenic doses of endotoxin are able to produce hypoferremila in man, and the lowering of serum iron corresponds to accumulation of iron in reticuloendothelial cells (6) . Similarly, intravenous injection of LP also results in acute hypoferremia (36) . Moreover, LPinduced hypoferremia is dependent on neutrophils since it does not occur in neutropenic animals (2) and the factor in neutrophils responsible for lowering of serumii iron has been shown to be lactoferrin (3). This glycoprotein, which exists in the neutrophil in the ironfree state (apolactoferrin), avidly binds serum iron, lowers serum iron in a dose-dependent fashion, and after the injection of 59Fe has been shown to accumulate in the satuirated state (59Fe-lactoferrin) in the reticuloendothelial systeimi (3).
Our observations provide a possible explanation for the intermiiediate step of' apolactoferrin release from neutroplhils in inflamnmatory states. In addition, since apolactoferrin is capable of removing Fe from transf'errin-Fe2 unider conditionis found in inflammatory sites (e.g. acidic pH) and Fe-lactoferrin is preferentially cleared from the circulation (3), the equilibrium reaction:
Transferrin-Fe., + apolactoferrin i apotransferrini + lactoferrin-Fe2, is constantly shifted to the right. The clinical observation that the hypof'erremic hypochromic anemia accompanying inflammation is generally unresponsive to Fe therapy is not surprising since even small amounts of released apolactoferrin would favor accumulation of' Fe-lactoferrin in the reticuloendothelial systemii and thereby reduce the amount of iron available for hematopoiesis. Whether other sub-stances accompanying acute inflammation are also able to induce neutrophil apolactoferrin release remains to be determined.
The kinetic factors responsible for elevated serum lysozyme in inflammatory and myeloproliferative disorders have been extensively investigated. It is well established that renal clearance accounts for the majority of lysozyme elimination. In anephric patients, for example, lysozyme clearance is only 15% of the rate found in normals (37) . In regard to production and release, txvo major f:actors have been defined that relate to serum lysozyme: (a) the syinthesis and release of lysozyme from leuikocytes and (b) the total size of the granulocyte and monocyte pools. In studies by Bodel et al. (38) , the lysozyme secretory rate by monocytes from patients with sareordosis has been shown to be significantly greater than controls and to directly correlate with serumii lysozyme levels. Furthermore, these moniocytes produce excessive LP in response to endotoxin. Hansen and Anderseni (4) have demonstrated that neutrophils isolated fromii patienits with acute bacterial infections contained 50% less lysozyme than conitrol neutrophils. To account for this finding, these authors suggested that bacterial infection suppressed neutrophil lysozyme synthesis. However, in preliminary studies, we have observed that after a single intraveniouis injectioni of bacterial enidotoxin into two normal vol unteers, mature neutrophils isolated from peripheral blood contained significantly less total lysozyme at 4 h than at 0 or 24 h (27.6+(0.2, 23.6+0.4, and 29.2+0.5 gg/5 x 106 neutrophils at 0, 4, and 24 h, respectively, P < 0.02 comparing the 4-h lysozyme content to 0 and 24 h). Thus, our in vitro and in vivo data suggest that the reduced neutrophil lysozymie content may reflect, at least in part, netutrophil secretion in response to pyrogen.
In myeloproliferative disorders, the size of the granuilocyte andI monocvte pools has been repeatedly shown to correlate with serumil lysozyme (39) . In both man and animals, the nadir of grainulocytes in druginduced leukopeniia corresponds to the nadir of serumn lysozyme. Similarly, the highest serum lysozyme levels are observed during marrow hyperplasia with increased granuilocyte aind moniocyte pools. It is interesting to note that LP has kAn effect on granulocyte turnover. Kampschimiidt and Upchutrch (40) have shown that repeated inijectionis of LP results in progressive increase in peripheral blood leukocytes. Moreover, in bone marrow culture, LP dramatically stimulated colony form-lation. Since LP hals multiple effects on factors known to effect serumil lysozyme, our observations of LP-induced lysozyme release may relate to only a portion of elevated sertumii lysozymne in inflamimatory and myeloproliferative disorders.
The demonstration that a biologic substance induces selective release of neutrophil specific granule contents which may be important in a number of inflammatory diseases provides new areas for assessing the clinical imlportance of both LP and neutrophil secretory products in the pathophysiology of inflammation.
